Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Real-World Evidence of Bevacizumab-awwb Use in a Population of Patients with Cancer

2021 Year in Review - Biosimilars - Biosimilars

Real-world evidence indicates robust biosimilar uptake of the first FDA-approved bevacizumab biosimilar, bevacizumab-awwb, across its approved indications, including metastatic colorectal cancer and non–small-cell lung cancer.

This retrospective, observational study evaluated the initial use of the first FDA-approved biosimilar to bevacizumab, bevacizumab-awwb, across its approved indications in real-world US community and academic oncology practices. The findings of the study were presented at the 2021 American Society of Clinical Oncology Annual Meeting.

This study utilized structured patient-level data from the electronic health record–derived Oncology Services Comprehensive Electronic Records database, which includes >2.2 million US patients with cancer from >280 cancer clinics. Inclusion criteria for this analysis were adult patients who received ≥1 bevacizumab-awwb infusions between July 30, 2019, and April 30, 2020.

A total of 2422 patients were treated with bevacizumab-awwb and included all approved cancer indications. Biosimilar uptake was most prevalent in metastatic colorectal cancer (68%), followed by non–small-cell lung cancer (14%), brain cancer (11%), cervical cancer (5%), and metastatic renal-cell carcinoma (1%). Among 1657 patients with metastatic colorectal cancer who were administered bevacizumab-awwb, 59% had prior bevacizumab reference exposure; of these, 67% received bevacizumab-awwb within 28 days of the last infusion of the reference product. Baseline and clinical characteristics were comparable between the patient cohorts with and without prior bevacizumab exposure.

Based on these results, the authors concluded that physicians are comfortable initiating or transitioning patients to bevacizumab-awwb across its indications.

Source: Jin R, Accortt NA, Sandschafer D, et al. Initial experience of patients treated in a real-world clinical setting with bevacizumab-awwb: the first FDA-approved biosimilar to bevacizumab. J Clin Oncol. 2021;39(suppl_3):81-81.

Related Items
Pharmacist-Driven Intervention Significantly Increases Biosimilar Adoption in Clinical Practice
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Biosimilars
Oncologists’ Common Misconceptions About Biosimilars Revealed in a Recent Survey
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Biosimilars
2021 in Review
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Real-World Data Showed Comparable pCR Rates with Neoadjuvant Chemotherapy plus Trastuzumab-dkst versus Trastuzumab
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Cost-Efficiency Analysis of Switching from Reference Pegfilgrastim to Pegfilgrastim-jmdb
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Incidence of Hypertension and Proteinuria in Bevacizumab- and Bevacizumab Biosimilar-Treated Cohorts
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Real-World Evidence of Cardiac Safety of Trastuzumab Biosimilar Trastuzumab-anns in Breast Cancer
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Same-Day Pegfilgrastim-cbqv Administration Is Feasible in Patients with Breast Cancer Receiving Myelosuppressive Chemotherapy Regimens
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Real-World Utilization and Cost Patterns with Biosimilar and Filgrastim Reference in a Community Oncology Setting
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Real-World Trends in Biosimilar Prescribing Among Oncology Providers
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.